{"cluster": 36, "subcluster": 0, "abstract_summ": "There is currently insufficient evidence to determine whether patients on systemic immunomodulators are at increased risk of developing COVID\u201019 disease or more likely to have severe disease.In patients with suspected or confirmed COVID\u201019 disease, all immunomodulators used for skin diseases should be immediately withheld, with the possible exception of systemic corticosteroid therapy, which needs to be weaned.In this review, we discuss overall infection risks of non\u2010biologic and biologic systemic medications for psoriasis and atopic dermatitis, and provide therapeutic recommendations.SUMMARY: Future research will need to evaluate the short- and long-term effectiveness of the therapy in the real-world setting, predictors of important treatment outcomes, and the use of adjunctive therapies that may mitigate some of these allergic reactions.Among the conventional therapies, methotrexate, azathioprine and mycophenolate mofetil increase the risk of infection, and thus their use is recommended only when necessary and at low doses.", "title_summ": "COVID\u201019 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statementReducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, CanadaConsiderations for Safety in the Use of Systemic Medications for Psoriasis and Atopic Dermatitis during the COVID\u201019 pandemicPeanut Oral Immunotherapy: a Current PerspectiveNew and Emerging Systemic Treatments for Atopic DermatitisImmunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days.", "title_abstract_phrases": "There is currently insufficient evidence to determine whether patients on systemic immunomodulators are at increased risk of developing COVID\u201019 disease or more likely to have severe disease.In patients with suspected or confirmed COVID\u201019 disease, all immunomodulators used for skin diseases should be immediately withheld, with the possible exception of systemic corticosteroid therapy, which needs to be weaned.In this review, we discuss overall infection risks of non\u2010biologic and biologic systemic medications for psoriasis and atopic dermatitis, and provide therapeutic recommendations.Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, CanadaPURPOSE: People with cancer face an elevated risk of infection and severe sequelae from COVID-19.SUMMARY: Future research will need to evaluate the short- and long-term effectiveness of the therapy in the real-world setting, predictors of important treatment outcomes, and the use of adjunctive therapies that may mitigate some of these allergic reactions."}